Brand and Other Names:Zerit, d4T
- Classes: HIV, NRTIs
Dosing & Uses
Dosage Forms & Strengths
- 1mg/mL (200mL)
>60 kg: 40 mg PO BID
<60 kg: 30 mg PO BID
- CrCl >50 mL/min: 40 mg PO q12hr
- CrCl 26-50 mL/min: 20 mg PO q12hr
- CrCl 10-25 mL/min: 20 mg PO qD
- CrCl >50 mL/min: 30 mg PO q12hr
- CrCl 26-50 mL/min: 15 mg PO q12hr
- CrCl 10-25 mL/min: 15 mg PO qD
Serious - Use Alternative
Significant - Monitor Closely
Incr hepatic transaminases
Metabolic disorders: lipoatrophy, lipodystrophy
Black Box Warnings
Fatal and nonfatal pancreatitis reported; suspend if pancreatitis suspected and discontinue if confirmed
Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) reported with use of nucleoside analogues alone or in combination
Fatal lactic acidosis reported in pregnant women who have received didanosine and stavudine with other antiretroviral agents. Use the combination with caution in pregnant women
Risk of potentially fatal lactic acidosis & severe hepatomegaly with steatosis, with use alone & especially with didanosine
Risk of potentially fatal pancreatitis when used with didanosine
Decr dose in renal impairment
Risk of immune reconstitution syndrome if used in combination w/ other antiretroviral drugs
Randomized controlled trials found lipoatrophy or lipodystrophy developed in a higher proportion of patients treated with stavudine compared to other nucleosides (tenofovir or abacavir)
Pregnancy & Lactation
Pregnancy Category: C
Lactation: HIV+ women are advised not to breastfeed
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Half-Life: 1-1.6 hr
Peak Plasma Time: 1 hr; 3 hr (XR)
Peak Plasma Concentration: (conventional) 228±62 ng/mL; (XR) 536±146 ng/mL
AUC: (conventional) 1966±629 ng.hr/mL; (XR) 2568±454 ng.hr/mL
Vd: 0.5 L/kg
Clearance: 594±165 mL/min (total body); 237±98 mL/min (renal)
Mechanism of Action
Nucleoside Reverse Transcriptase Inhibitor (NRTI)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs